NCT05924256

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, open-label, phase 2 study to evaluate the efficacy and safety of target therapy for patients with relapsed/metastastic salivary gland carcinoma based on molecular typing.

Detailed description

Patients with IHC HER2 IHC 3+ or IHC 2+/ISH+ will be located into arm 1 to receive anti-her2 ADC（SHR- A1811） Patients with IHC AR positive will be located into arm 2 to receive anti-androgen therapy (SHR-3680)+leuprolide Patients with HER2 negative and AR negative will be located into arm 3 to receive anti-TROP2 ADC (SHR-A1921) Patients with IHC HER2 IHC 1+ or IHC 2+/ISH- will be located into arm 4 to receive anti-her2 ADC（SHR- A1811）

Conditions

• Advanced Salivary Gland Carcinoma

Interventions

Type	Name	Description
DRUG	SHR-A1811	SHR-A1811
DRUG	SHR 3680 + leuprolide	SHR 3680 + leuprolide
DRUG	SHR-A1921	SHR-A1921
DRUG	SHR-A1811	SHR-A1811

Timeline

• Start date: 2023-07-26
• Primary completion: 2026-12-30
• Completion: 2026-12-30
• First posted: 2023-06-29
• Last updated: 2026-04-02

Locations

1 site across 1 country: China